Abstract
[reaction: see text] A recombinant P450-monooxygenase, DoxA, obtained from Streptomyces sp. strain C5, the producer of the anticancer compound daunorubicin, was expressed in S. lividans TK24 and therein used to catalyze the conversion of the anthracycline analogue desacetyladriamycin into the new anthracycline, 10-hydroxydesacetyladriamycin. This work establishes a new function for DoxA and demonstrates the use of a recombinant enzyme to prepare a new anthracycline analogue.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Antibiotics, Antineoplastic / biosynthesis
-
Antibiotics, Antineoplastic / metabolism*
-
Bacterial Proteins*
-
Cytochrome P-450 Enzyme System / biosynthesis
-
Cytochrome P-450 Enzyme System / genetics
-
Cytochrome P-450 Enzyme System / metabolism*
-
Doxorubicin / analogs & derivatives
-
Doxorubicin / biosynthesis*
-
Doxorubicin / metabolism*
-
Hydroxylation
-
Mixed Function Oxygenases / biosynthesis
-
Mixed Function Oxygenases / genetics
-
Mixed Function Oxygenases / metabolism*
-
Nuclear Magnetic Resonance, Biomolecular
-
Recombinant Proteins / biosynthesis
-
Recombinant Proteins / genetics
-
Recombinant Proteins / metabolism
-
Streptomyces / enzymology*
-
Streptomyces / genetics
-
Streptomyces / metabolism
Substances
-
10-hydroxydesacetyladriamycin
-
Antibiotics, Antineoplastic
-
Bacterial Proteins
-
Recombinant Proteins
-
desacetyladriamycin
-
Doxorubicin
-
Cytochrome P-450 Enzyme System
-
Mixed Function Oxygenases
-
doxA protein, Streptomyces peucetius